Lower Insulin-Dose Adjusted A1c (IDAA1c) Is Associated With Less Complications in Individuals With Type 1 Diabetes Treated With Hematopoetic Stem-Cell Transplantation and Conventional Therapy-Reference-Cited by-同舟云学术

Lower Insulin-Dose Adjusted A1c (IDAA1c) Is Associated With Less Complications in Individuals With Type 1 Diabetes Treated With Hematopoetic Stem-Cell Transplantation and Conventional Therapy

Published:2019-11-19 Issue: Volume:10 Page:
ISSN:1664-2392
Container-title:Frontiers in Endocrinology
language:
Short-container-title:Front. Endocrinol.

Author:

Penaforte-Saboia Jaquellyne Gurgel,Couri Carlos Eduardo Barra,Fernandes Virginia Oliveira,Montenegro Ana Paula Dias Rangel,Batista Lívia Aline De Araújo,Zajdenverg Lenita,Negrato Carlos Antonio,Malmegrim Kelen Cristina Ribeiro,Moraes Daniela Aparecida,Dias Juliana Bernardes Elias,Oliveira Maria Carolina,Hussain Akhtar,Gomes Marilia Brito,Montenegro Renan Magalhães

Publisher

Frontiers Media SA

Subject

Endocrinology, Diabetes and Metabolism

Reference52 articles.

1. Low levels of C-peptide have clinical significance for established Type 1 diabetes;Kuhtreiber;Diabet Med.,2015

2. Relationships among islet cell antibodies, residual β-cell function, and metabolic control in patients with insulin-dependent diabetes mellitus of long duration: use of a sensitive C-peptide radioimmunoassay;Nakanishi;Metabolism.,1990

3. Residual B-cell function and HLA-A24 in IDDM, markers of glycemic control and subsequent development of diabetic retinopathy;Nakanishi;Diabetes.,1995

4. Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin dependent) diabetes mellitus;Sjöberg;Diabetologia.,1987

5. C-peptide in juvenile diabetics beyond the postinitial remission period;Ludvigsson;Acta Paediatr Scand.,1977

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of HNFA1 Gene Variants in Pancreatic Beta Cells Function and Glycaemic Control in Young Individuals with Type 1 Diabetes;Biomedicines;2023-07-10

2. First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes;BMC Medicine;2023-05-24